Status:
UNKNOWN
OPG and RANKL Plasma Level After Administration of Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH) in Hemodialysis
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Renal Failure
Hemodialysis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A randomised, prospective, cross over study will be done to determine whether the anticoagulation therapy with UFH or LMWH used for hemodialysis sessions modifies osteoprotegerin and RANKL plasma leve...
Detailed Description
It's well known that treatment with heparin can lead to a reduction in bone density and the development of osteoporosis \[ 1 \]. Until now, it's not clear the mechanism by which heparin produces this ...
Eligibility Criteria
Inclusion
- hemodialysis patients with age \> 18 years on regular bicarbonate hemodialysis or hemodiafiltration treatment three times a week;
- clinical stability at least three months before the study started;
Exclusion
- active gastrointestinal bleeding (one ore more positive hemoccult test in the last 8 weeks, melena or proctoraggia in the last 6 months )
- hemorrhagic stroke
- Myeloproliferative disorders
- Hereditary deficiency of coagulation factors, LAC phenomenon or antiphospholipid syndrome
- Malignant disease
- Patient submitted to antithrombotic prophylaxis with LMWH
- Immunosuppressive therapy
- Participation in other clinical trials
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00669721
Start Date
March 1 2008
End Date
June 1 2008
Last Update
April 30 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St.Orsola University Hospital
Bologna, Italy, 40100